Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Adelstein

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Expert Opinion on Pharmacotherapy|October 30, 2015
Pharmacotherapy of head and neck cancerTobenna Nwizu, David Adelstein
Cleveland Clinic Journal of Medicine|October 20, 2005
A woman with headache and blurred visionEna Segota, David Adelstein, Tarek Mekhail
The Laryngoscope|September 12, 2017
Elucidation of salvage laryngectomy pathologic and clinical variables to guide further treatment intensification investigationJoseph Scharpf, Matthew Ward, David Adelstein, et al.
Medical Oncology (Northwood, London, England)|February 17, 2007
Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancerSujith Kalmadi, Giles McNeill, Mellar Davis, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|December 4, 2004
Functional outcomes following chemoradiotherapy for head and neck cancerLee M Akst, James Chan, Paul Elson, et al.
Anticancer Research|July 31, 2020
Detection and Oncologic Outcomes of Head and Neck Squamous Cell Carcinoma of Unknown Primary OriginMaxwell Y Lee, Nicole Fowler, David Adelstein, et al.
Oral Oncology|January 2, 2018
Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysisPetr Szturz, Kristien Wouters, Naomi Kiyota, et al.
Frontiers in Oncology|March 9, 2019
Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck CancerPetr Szturz, Kristien Wouters, Naomi Kiyota, et al.
The Oncologist|May 24, 2017
Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate DataPetr Szturz, Kristien Wouters, Naomi Kiyota, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 18, 2016
Importance of residual primary cancer after induction therapy for esophageal adenocarcinomaSiva Raja, Thomas W Rice, John Ehrlinger, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Expert Opinion on Pharmacotherapy|October 30, 2015
Pharmacotherapy of head and neck cancerTobenna Nwizu, David Adelstein
Cleveland Clinic Journal of Medicine|October 20, 2005
A woman with headache and blurred visionEna Segota, David Adelstein, Tarek Mekhail
The Laryngoscope|September 12, 2017
Elucidation of salvage laryngectomy pathologic and clinical variables to guide further treatment intensification investigationJoseph Scharpf, Matthew Ward, David Adelstein, et al.
Medical Oncology (Northwood, London, England)|February 17, 2007
Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancerSujith Kalmadi, Giles McNeill, Mellar Davis, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|December 4, 2004
Functional outcomes following chemoradiotherapy for head and neck cancerLee M Akst, James Chan, Paul Elson, et al.
Anticancer Research|July 31, 2020
Detection and Oncologic Outcomes of Head and Neck Squamous Cell Carcinoma of Unknown Primary OriginMaxwell Y Lee, Nicole Fowler, David Adelstein, et al.
Oral Oncology|January 2, 2018
Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysisPetr Szturz, Kristien Wouters, Naomi Kiyota, et al.
Frontiers in Oncology|March 9, 2019
Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck CancerPetr Szturz, Kristien Wouters, Naomi Kiyota, et al.
The Oncologist|May 24, 2017
Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate DataPetr Szturz, Kristien Wouters, Naomi Kiyota, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 18, 2016
Importance of residual primary cancer after induction therapy for esophageal adenocarcinomaSiva Raja, Thomas W Rice, John Ehrlinger, et al.
Pageof 2